UGGT1

UGGT1 is an ER-resident glucosyltransferase that operates as a central folding sensor in N-glycoprotein quality control, recognizing incompletely folded glycoproteins and reglucosylating their N-linked glycans to govern their fate (PMID:33320095, PMID:39654396). It is the dominant cellular reglucosylating enzyme, with substrate preference biased toward large, heavily glycosylated plasma membrane proteins (PMID:33320095). Mechanistically, monoglucosylation increases the solubility of misfolded glycoproteins, reduces their BiP association, and dampens UPR activation in a calreticulin-dependent manner (PMID:23864712), while delaying degradation by competing with EDEM-mediated mannose trimming — an activity that requires UGGT1 catalytic function and is needed for ATF6α to function properly (PMID:39654396). Through reglucosylation UGGT1 retains misfolded substrates in the ER, including disease-associated Trop-2 mutants whose plasma membrane localization is rescued by UGGT1 deletion (PMID:38272446, PMID:37398215) and proinsulin, whose ER exit and downstream insulin secretion are gated by arginine competition for a C-terminal binding domain (PMID:32423812, PMID:35613513). UGGT1 also enforces a BiP- and calnexin-independent membrane checkpoint in cooperation with the AAA-ATPase p97 (PMID:25694454) and contributes to MHC I antigen-presentation quality control by reglucosylating peptide-receptive MHC I in concert with TAPBPR and calreticulin (PMID:37345806). Bi-allelic UGGT1 variants that impair catalytic activity, splicing, or ER retention cause a congenital disorder of glycosylation (UGGT1-CDG), with loss-of-function variants linked to greater severity (PMID:40267907).

1. 2009 Low

   An early functional screen asked whether UGGT1 levels influence ER homeostasis, linking it to BiP-dependent stress signaling and recombinant protein output.

   Evidence cDNA screen with a BiP promoter reporter and UGGT1 overexpression in HEK293 cells measuring recombinant protein production

   PMID:19466607

   Open questions at the time

   • Single overexpression screen with no mechanistic dissection of how UGGT1 activates the BiP promoter
   • Does not distinguish direct catalytic effect from indirect stress induction
2. 2013 High

   Established the biochemical consequence of UGGT1 reglucosylation for misfolded substrates: increased solubility, reduced chaperone burden, and tempered UPR — defining its pro-folding role rather than mere recognition.

   Evidence UGGT1-null and complemented mouse embryonic fibroblasts with solubility fractionation, BiP co-IP, UPR reporters, and calreticulin-deficient cells using α1-antitrypsin NHK/Z variants

   PMID:23864712

   Open questions at the time

   • Mechanism by which calreticulin dependence translates monoglucosylation into solubility is not resolved
   • Limited to α1-antitrypsin model substrates
3. 2015 Medium

   Showed UGGT1 quality control extends to intramembrane defects, operating in a checkpoint independent of BiP and calnexin and shared with cytosolic p97.

   Evidence Modular chimeric glycopolypeptide reporters in human cells with UGGT1 siRNA, pharmacological inhibition, and Golgi transport assays

   PMID:25694454

   Open questions at the time

   • Physical/functional coupling between luminal UGGT1 and cytosolic p97 not defined
   • siRNA plus inhibitor only; no catalytic-dead rescue
4. 2020 High

   Defined the endogenous substrate landscape and division of labor between paralogs, identifying UGGT1 as the dominant enzyme with selectivity for large, heavily glycosylated membrane proteins.

   Evidence Quantitative glycoproteomics in CRISPR-edited HEK293 cells at endogenous expression levels

   PMID:33320095

   Open questions at the time

   • Structural basis for size/glycan preference unknown
   • Does not address folding outcome for each substrate
5. 2020 Medium

   Revealed a regulatory, metabolite-gated function: UGGT1 directly binds and retains proinsulin, with arginine availability releasing it to drive insulin secretion.

   Evidence Affinity nanobead pulldown, arginine/proinsulin competition binding, and insulin secretion assays in β-cell models

   PMID:32423812

   Open questions at the time

   • Whether retention is glycan-dependent reglucosylation or direct protein binding is unresolved
   • Physiological arginine ranges and in vivo relevance not established
6. 2022 Medium

   Mapped the proinsulin/arginine binding determinants, separating substrate binding (R1526) from arginine binding and showing the C-terminal ER retention signal is required to prevent secretion.

   Evidence SNP library screening, co-IP of UGGT1 variants with proinsulin, structural prediction, and secretion assays

   PMID:35613513

   Open questions at the time

   • No structural model of the A/PBD validated experimentally
   • Functional consequences for non-proinsulin substrates untested
7. 2023 High

   Reconstituted UGGT1's role in antigen presentation, demonstrating TAPBPR-promoted reglucosylation of peptide-free MHC I with purified components.

   Evidence In vitro reconstitution of purified human proteins with glycoengineering and LC-MS glycan readout

   PMID:37345806

   Open questions at the time

   • Cellular contribution to peptide selection not quantified
   • Single-lab reconstitution
8. 2024 High

   Established that reglucosylation actively delays glycoprotein degradation by competing with EDEM mannose trimming, and that this catalytic activity is required for ATF6α function.

   Evidence UGGT1/2 CRISPR disruption plus glucosylation-dead point mutant with pulse-chase degradation, overexpression competition, and ATF6α functional assays

   PMID:39654396

   Open questions at the time

   • Quantitative kinetics of the UGGT1-vs-EDEM competition not modeled
   • How ATF6α dependence integrates with broader UPR output unclear
9. 2024 High

   Linked UGGT1 reglucosylation to a human disease mechanism, showing it retains misfolded Trop-2 mutants in the ER and that its deletion rescues their surface trafficking.

   Evidence CRISPR/Cas9 UGGT1/UGGT2 knockout HEK293 cells, confocal imaging of Trop-2 chimeras, and in cellula reglucosylation assays across multiple mutants

   PMID:37398215 PMID:38272446

   Open questions at the time

   • Whether rescued mutants are functionally competent at the surface untested
   • Generality to other dystrophy-causing membrane proteins unknown
10. 2025 Medium

    Connected UGGT1 directly to inherited disease, demonstrating that bi-allelic variants impairing catalysis, splicing, or ER retention cause a congenital disorder of glycosylation.

    Evidence Functional characterization of patient-derived variants (glucosylation activity, splicing, ER retention) with genotype-phenotype correlation across 15 individuals from 10 families

    PMID:40267907

    Open questions at the time

    • Tissue-specific basis of phenotypes not defined
    • Single publication; cohort size limited

• How UGGT1 mechanistically distinguishes folded from misfolded substrates and how its checkpoint activities (p97, ATF6α, MHC I, metabolite gating) are coordinated within the ER quality-control network remains unresolved.
• No structure of substrate-bound UGGT1 explaining misfold recognition
• Integration of UGGT1 across distinct quality-control branches not unified mechanistically